307 related articles for article (PubMed ID: 25556837)
1. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.
Mouly S; Bloch V; Peoc'h K; Houze P; Labat L; Ksouda K; Simoneau G; Declèves X; Bergmann JF; Scherrmann JM; Laplanche JL; Lepine JP; Vorspan F
Br J Clin Pharmacol; 2015 Jun; 79(6):967-77. PubMed ID: 25556837
[TBL] [Abstract][Full Text] [Related]
2. Assessment of CYP450 genetic variability effect on methadone dose and tolerance.
Tsai HJ; Wang SC; Liu SW; Ho IK; Chang YS; Tsai YT; Lin KM; Liu YL
Pharmacogenomics; 2014 May; 15(7):977-86. PubMed ID: 24956251
[TBL] [Abstract][Full Text] [Related]
3. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O; Peles E; Hamon S; Randesi M; Adelson M; Kreek MJ
Addict Biol; 2013 Jul; 18(4):709-16. PubMed ID: 21790905
[TBL] [Abstract][Full Text] [Related]
4. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
5. Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.
Wang SC; Ho IK; Tsou HH; Liu SW; Hsiao CF; Chen CH; Tan HK; Lin L; Wu CS; Su LW; Huang CL; Yang YH; Liu ML; Lin KM; Liu SC; Wu HY; Kuo HW; Chen AC; Chang YS; Liu YL
OMICS; 2013 Oct; 17(10):519-26. PubMed ID: 24016178
[TBL] [Abstract][Full Text] [Related]
6. PXR polymorphisms interacted with CYP2B6 polymorphisms on methadone metabolites.
Tsai HJ; Wang SC; Tian JN; Chang TK; Ho IK; Hsiao CF; Chen CH; Tan HK; Lin L; Wu CS; Su LW; Huang CL; Yang YH; Liu ML; Lin KM; Liu YL
J Clin Psychopharmacol; 2013 Feb; 33(1):137-40. PubMed ID: 23288240
[No Abstract] [Full Text] [Related]
7. Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use.
Ramli FF
Bosn J Basic Med Sci; 2021 Apr; 21(2):145-154. PubMed ID: 32841585
[TBL] [Abstract][Full Text] [Related]
8. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
9. Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients.
Yang HC; Chu SK; Huang CL; Kuo HW; Wang SC; Liu SW; Ho IK; Liu YL
PLoS Genet; 2016 Mar; 12(3):e1005910. PubMed ID: 27010727
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients.
Wang SC; Tsou HH; Chen CH; Chen YT; Ho IK; Hsiao CF; Chou SY; Lin YF; Fang KC; Huang CL; Su LW; Fang YC; Liu ML; Wu HY; Lin KM; Liu SC; Kuo HW; Chiang IC; Chen AC; Tian JN; Liu YL
Eur Neuropsychopharmacol; 2012 Oct; 22(10):695-703. PubMed ID: 22406240
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients.
Hung CC; Chiou MH; Huang BH; Hsieh YW; Hsieh TJ; Huang CL; Lane HY
Pharmacogenomics; 2011 Nov; 12(11):1525-33. PubMed ID: 21902500
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients.
Chen CH; Wang SC; Tsou HH; Ho IK; Tian JN; Yu CJ; Hsiao CF; Chou SY; Lin YF; Fang KC; Huang CL; Su LW; Fang YC; Liu ML; Lin KM; Hsu YT; Liu SC; Chen ACh; Liu YL
Pharmacogenomics; 2011 Oct; 12(10):1397-406. PubMed ID: 21902501
[TBL] [Abstract][Full Text] [Related]
13. Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.
Dennis BB; Bawor M; Thabane L; Sohani Z; Samaan Z
PLoS One; 2014; 9(1):e86114. PubMed ID: 24489693
[TBL] [Abstract][Full Text] [Related]
14. OPRM1 and CYP3A4 association with methadone dose in Iranian patients undergoing methadone maintenance therapy.
Akbari A; Kheradmand A; Sina M; Ahmadiani A; Asadi S
J Addict Dis; 2021; 39(3):357-362. PubMed ID: 33682628
[TBL] [Abstract][Full Text] [Related]
15. The opiate dosage adequacy scale for identification of the right methadone dose--a prospective cohort study.
Walcher S; Koc J; Reichel V; Schlote F; Verthein U; Reimer J
BMC Pharmacol Toxicol; 2016 Apr; 17():15. PubMed ID: 27052201
[TBL] [Abstract][Full Text] [Related]
16. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
17. Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.
Kringen MK; Chalabianloo F; Bernard JP; Bramness JG; Molden E; Høiseth G
Ther Drug Monit; 2017 Oct; 39(5):550-555. PubMed ID: 28723731
[TBL] [Abstract][Full Text] [Related]
18. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of methadone maintenance treatment.
Somogyi AA; Barratt DT; Ali RL; Coller JK
Pharmacogenomics; 2014 May; 15(7):1007-27. PubMed ID: 24956254
[TBL] [Abstract][Full Text] [Related]
20. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
